North America Epirubicin Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Dosage (10mg/Vial, 50mg/Vial, 100mg/Vial, and 200mg/Vial), Application (Breast Cancer, Liver Cancer, Bladder Cancer, and Others), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
The North America epirubicin market is expected to grow from US$ 95,445.28 thousand in 2022 to US$ 1,18,596.58 thousand by 2028; it is estimated to grow at a CAGR of 3.7% from 2022 to 2028.
Rising FDA Approvals for Cancer Drugs Offers Lucrative Market Opportunities
On June 22, 2022, the US Food and Drug Administration (FDA) granted accelerated approval to the usage of dabrafenib, which is sold under the brand name Tafinlar by Novartis in combination with trametinib that is sold under the brand name Mekinist by Novartis to treat patients, especially pediatric patients above six years of age, with solid metastatic tumors with BRAF V600E mutation. On December 1, 2017, the FDA approved Ogivri (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) to treat breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors isoform the HER2 gene (HER2+). On May 27, 2022, the FDA approved Nvolumab, which is sold under the brand name Opdivo by Bristol-Myers Squibb Company, in combination with fluoropyrimidine- and platinum-based chemotherapy and nivolumab in combination with ipilimumab that is sold under the brand name Yervoy by Bristol-Myers Squibb Company for the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) patients. On March 11, 2022, the FDA approved olaparib that is sold under the brand name Lynparza by AstraZeneca Pharmaceuticals, L.P. for treating breast cancer patients. Further, in May 2021, the FDA granted accelerated approval to combining the immunotherapy drug pembrolizumab (Keytruda) with standard treatments for patients with HER2+ tumors of the esophagus or stomach. Thus, the rising number of FDA approvals is offering lucrative opportunities for the epirubicin market growth.
Market Overview
The North America epirubicin market is segmented into the US, Canada, and Mexico. The US held the largest share of the market in 2021. The rising prevalence of breast cancer, growing research & development activities, and increasing demand for advanced therapeutic solutions to treat cancer are among the prominent factors propelling the market growth. The increasing prevalence of breast cancer in the US is likely to increase the demand for epirubicin. According to the Centers for Disease Control and Prevention (CDC), every year in the US, ~2,64,000 cases of breast cancer are diagnosed in women and ~2,400 in men. Further, epirubicin is also used to treat bladder cancer. The American Cancer Society estimated that by the end of 2022, there will be 81,180 new cases of bladder cancer. Additionally, the US pharmaceutical market is the largest and the most commercial market in North America; it holds over 45% of the global pharmaceutical market. The majority of the leading global drug manufacturing companies are US-based that are active in the manufacturing of medical devices/diagnostics and consumer products. Thus, the increasing prevalence of cancer in the country is anticipated to boost the US epirubicin market growth during the forecast period.
North America Epirubicin Market Revenue and Forecast to 2028 (US$ Thousand)
North America Epirubicin Market Segmentation
The North America epirubicin market is segmented on the basis of dosage, application, distribution channel, and country. Based on dosage, the North America epirubicin market is segmented into 10mg/vial, 50mg/vial, 100mg/vial, and 200mg/vial. The 50mg/vial segment held the largest market share in 2022. Based on application, the North America epirubicin market is categorized into breast cancer, liver cancer, bladder cancer, and others. The breast cancer segment held the largest market share in 2022. Based on distribution channel, the North America epirubicin market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest market share in 2022. Based on country, the North America epirubicin market has been categorized into the US, Canada, and Mexico. Further, the US dominated the market in 2022.eva Pharmaceuticals, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Mylan N.V., Pfizer Inc., Salius Pharma Pvt Ltd, and Teva Pharmaceutical Industries Ltd. are the leading companies operating in the North America epirubicin market.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Epirubicin Market – By Dosage
1.3.2 North America Epirubicin Market – By Application
1.3.3 North America Epirubicin Market – By Distribution Channel
1.3.4 North America Epirubicin Market – By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Epirubicin Market – Market Landscape
4.1 Overview
4.2 North America PEST Analysis
4.3 Experts Opinion
5. North America Epirubicin Market– Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Cancer
5.1.2 Increasing Awareness Regarding Cancer
5.2 Market Restraints
5.2.1 Elevated Risk of Adverse Effects due to Epirubicin
5.3 Market Opportunities
5.3.1 Rising FDA Approvals for Cancer Drugs
5.4 Future Trends
5.4.1 Increase in Number of Cancer Research Programs
5.5 Impact Analysis
6. Epirubicin Market– North America Analysis
6.1 North America Epirubicin Market Revenue Forecasts and Analysis
7. North America Epirubicin Market Analysis – By Dosage
7.1 Overview
7.2 North America Epirubicin Market, by Dosage, 2022 & 2028 (%)
7.3mg/Vial
7.3.1 Overview
7.3.2mg/Vial Market Revenue and Forecast to 2028 (US$ Thousand)
7.4mg/Vial
7.4.1 Overview
7.4.2mg/Vial Market Revenue and Forecast to 2028 (US$ Thousand)
7.5mg/Vial
7.5.1 Overview
7.5.2mg/Vial Market Revenue and Forecast to 2028 (US$ Thousand)
7.6mg/Vial
7.6.1 Overview
7.6.2 Mg/Vial Market Revenue and Forecast to 2028 (US$ Thousand)
8. North America Epirubicin Market Analysis – By Application
8.1 Overview
8.2 North America Epirubicin Market, by Application, 2022 & 2028 (%)
8.3 Breast Cancer
8.3.1 Overview
8.3.2 Breast Cancer Market Revenue and Forecast to 2028 (US$ Thousand)
8.4 Liver Cancer
8.4.1 Overview
8.4.2 Liver Cancer Market Revenue and Forecast to 2028 (US$ Thousand)
8.5 Bladder Cancer
8.5.1 Overview
8.5.2 Bladder Cancer Market Revenue and Forecast to 2028 (US$ Thousand)
8.6 Others
8.6.1 Overview
8.6.2 Others Cancer Market Revenue and Forecast to 2028 (US$ Thousand)
9. North America Epirubicin Market Analysis – By Distribution Channel
9.1 Overview
9.2 North America Epirubicin Market, by Distribution Channel, 2022 & 2028 (%)
9.3 Hospital Pharmacies
9.3.1 Overview
9.3.2 Hospital Pharmacies Market Revenue and Forecast to 2028 (US$ Thousand)
9.4 Retail Pharmacies
9.4.1 Overview
9.4.2 Retail Pharmacies Market Revenue and Forecast to 2028 (US$ Thousand)
9.5 Online Pharmacies
9.5.1 Overview
9.5.2 Online Pharmacies Market Revenue and Forecast to 2028 (US$ Thousand)
10. North America Epirubicin Market – Country Analysis
10.1 North America: Epirubicin Market
10.1.1 Overview
10.1.2 North America: Epirubicin Market, by Country, 2022 & 2028 (%)
10.1.2.1 US: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.1.2.1.1 Overview
10.1.2.1.2 US: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.1.2.1.3 US: Epirubicin Market, by Dosage, 2019–2028 (US$ Thousand)
10.1.2.1.4 US: Epirubicin Market, by Application, 2019–2028 (US$ Thousand)
10.1.2.1.5 US: Epirubicin Market, by Distribution Channel, 2019–2028 (US$ Thousand)
10.1.2.2 Canada: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.1.2.2.1 Overview
10.1.2.2.2 Canada: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.1.2.2.3 Canada: Epirubicin Market, by Dosage, 2019–2028 (US$ Thousand)
10.1.2.2.4 Canada: Epirubicin Market, by Application, 2019–2028 (US$ Thousand)
10.1.2.2.5 Canada: Epirubicin Market, by Distribution Channel, 2019–2028 (US$ Thousand)
10.1.2.3 Mexico: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.1.2.3.1 Overview
10.1.2.3.2 Mexico: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.1.2.3.3 Mexico: Epirubicin Market, by Dosage, 2019–2028 (US$ Thousand)
10.1.2.3.4 Mexico: Epirubicin Market, by Application, 2019–2028 (US$ Thousand)
10.1.2.3.5 Mexico: Epirubicin Market, by Distribution Channel, 2019–2028 (US$ Thousand)
11. Industry Landscape
11.1 Overview
11.2 Growth Strategies
11.2.1 Overview
12. Company Profiles
12.1 Pfizer Inc.
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Teva Pharmaceutical Industries Ltd.
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Salius Pharma Pvt Ltd
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Areva Pharmaceuticals
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Mylan N.V.
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Hikma Pharmaceuticals PLC
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Fresenius Kabi AG
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
LIST OF TABLES
Table 1. North America Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
Table 2. US Epirubicin Market, by Dosage – Revenue and Forecast to 2028 (US$ Thousand)
Table 3. US Epirubicin Market, by Application – Revenue and Forecast to 2028 (US$ Thousand)
Table 4. US Epirubicin Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Thousand)
Table 5. Canada Epirubicin Market, by Dosage – Revenue and Forecast to 2028 (US$ Thousand)
Table 6. Canada Epirubicin Market, by Application – Revenue and Forecast to 2028 (US$ Thousand)
Table 7. Canada Epirubicin Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Thousand)
Table 8. Mexico Epirubicin Market, by Dosage – Revenue and Forecast to 2028 (US$ Thousand)
Table 9. Mexico Epirubicin Market, by Application – Revenue and Forecast to 2028 (US$ Thousand)
Table 10. Mexico Epirubicin Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Thousand)
Table 11. Recent Growth Strategies
Table 12. Glossary of Terms
LIST OF FIGURES
Figure 1. North America Epirubicin Market Segmentation
Figure 2. North America Epirubicin Market, By Country
Figure 3. North America Epirubicin Market Overview
Figure 4. North America Epirubicin Market, By Dosage
Figure 5. North America Epirubicin Market, By Country
Figure 6. North America: PEST Analysis
Figure 7. Experts Opinion
Figure 8. Impact Analysis of Drivers and Restraints on North America Epirubicin Market
Figure 9. North America Epirubicin Market – Revenue Forecasts and Analysis
Figure 10. North America Epirubicin Market, by Dosage, 2022 & 2028 (%)
Figure 11. North America 10mg/Vial Market Revenue and Forecast to 2028 (US$ Thousand)
Figure 12. North America 50mg/Vial Market Revenue and Forecast to 2028 (US$ Thousand)
Figure 13. North America 100mg/Vial Market Revenue and Forecast to 2028 (US$ Thousand)
Figure 14. North America 200 Mg/Vial Market Revenue and Forecast to 2028 (US$ Thousand)
Figure 15. North America Epirubicin Market, by Application, 2022 & 2028 (%)
Figure 16. North America Breast Cancer Market Revenue and Forecast to 2028 (US$ Thousand)
Figure 17. North America Liver Cancer Market Revenue and Forecast to 2028 (US$ Thousand)
Figure 18. North America Bladder Cancer Market Revenue and Forecast to 2028 (US$ Thousand)
Figure 19. North America Others Cancer Market Revenue and Forecast to 2028 (US$ Thousand)
Figure 20. North America Epirubicin Market, by Distribution Channel, 2022 & 2028 (%)
Figure 21. North America Hospital Pharmacies Market Revenue and Forecast to 2028 (US$ Thousand)
Figure 22. North America Retail Pharmacies Market Revenue and Forecast to 2028 (US$ Thousand)
Figure 23. North America Online Pharmacies Market Revenue and Forecast to 2028 (US$ Thousand)
Figure 24. North America: Epirubicin Market, by Key Country – Revenue (2022) (US$ Thousand)
Figure 25. North America: Epirubicin Market, by Country, 2022 & 2028 (%)
Figure 26. US: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
Figure 27. Canada: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
Figure 28. Mexico: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
- Areva Pharmaceuticals
- Fresenius Kabi AG
- Hikma Pharmaceuticals PLC
- Mylan N.V.
- Pfizer Inc.
- Salius Pharma Pvt Ltd
- Teva Pharmaceutical Industries Ltd.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America epirubicin market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the North America epirubicin market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth North America market trends and outlook coupled with the factors driving the epirubicin market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution